Neuphoria Therapeutics (NASDAQ: NEUP) reported a quarterly loss of $(0.95) per share, missing the analyst consensus estimate of $(0.56) by nearly 70%. The result represents a significant deterioration from the prior year period.

The company’s financial performance showed mixed signals during the quarter. While earnings per share deteriorated sharply, revenue generation remained active with reported sales of $1.174 million. This revenue figure provides context for the operational scale against which the per-share losses were calculated.

What the Numbers Show

The divergence between the current quarter's loss and the prior year's figure highlights a shift in profitability dynamics. The current loss of $(0.95) per share is substantially lower in magnitude than the $(3.98) per share loss recorded in the same period last year. Despite this reduction in absolute loss per share, the source characterizes this change as a 76.13% increase over the previous period's losses, indicating a complex reporting metric or base effect that readers should note alongside the raw figures.

The miss against the analyst estimate of $(0.56) suggests that market expectations for cost control or revenue conversion were not met during this reporting cycle. With no data provided on operating expenses or gross margins, the specific driver of the wider-than-expected loss remains opaque, though the total sales volume of $1.174 million offers a baseline for top-line activity.

Neuphoria Therapeutics Inc. confirmed on June 26, 2026, that its Board is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition. The talks follow an announcement by Scancell earlier in the day, which was made in response to speculation in the UK press and in compliance with UK regulations. If a transaction is completed, Scancell would become a Nasdaq-listed company.

The Neuphoria Board stated that there can be no certainty that any agreement will be reached, nor regarding the terms of any transaction or if any transaction will proceed at all. Any further announcements will be made in compliance with applicable SEC and Nasdaq regulations.

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing therapies for neuropsychiatric disorders. The company is advancing BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor for the treatment of post-traumatic stress disorder (PTSD). Following the announcement from the AFFIRM-1 Phase 3 clinical trial on October 20, 2025, in which the trial missed its primary and secondary endpoints, the company halted development of BNC210 in social anxiety disorder and is conducting a strategic review.

Neuphoria also holds a strategic partnership for two drugs in early-stage clinical trials for cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Its pipeline includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.